Page 5 - Early Access Program News Today : Breaking News, Live Updates & Top Stories | Vimarsana

LYON, France, March 12, 2024--Regulatory News: MaaT Pharma (EURONEXT: MAAT – the "Company"), a clinical-stage biotechnology company and a leader in the development of Microbiome Ecosystem TherapiesTM (MET) dedicated to enhancing survival for patients with cancer, will present extended results from its Early Access Program for patients with aGvHD that were treated with MaaT013 and, for the first time, Overall Survival data after 12 months in more patients. The data will be shared during an oral p

PARIS--(BUSINESS WIRE)--Mar 12, 2024--

Press release MaaT Pharma Announces Long Term Follow-Up Data for MaaT013 in Early Access Program to be Presented at the Upcoming EBMT Conference ...

- Petosemtamab in 1L HNSCC in combination with pembrolizumab initial interim clinical data planned for 2Q24; preparing for a potential phase 3 trial - Petosemtamab in 2L+ HNSCC phase 3 trial planned to initiate mid-2024; interim clinical data planned for 2H24 - Petosemtamab in 2L CRC: cohort planned to initiate in 2024 - Zeno in NRG1+ cancer: Sufficient clinical data expected in 1H24 to support potential BLA submissions - Based on the Company’s current operating plan, existing cash, cash equival

Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) Q4 2023 Earnings Call Transcript February 22, 2024 Rhythm Pharmaceuticals, Inc. reports earnings inline with expectations. Reported EPS is $-0.7 EPS, expectations were $-0.7. Rhythm Pharmaceuticals, Inc. isn’t one of the 30 most popular stocks among hedge funds at the end of the third quarter (see the details here). Operator: Ladies […]